Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Name: Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study
Creator: Joslyn Kirby
Published: 2023-10-13T14:25:56.794Z
Keywords: Hidradenitis Suppurativa

Kirby, Joslyn

doi:10.17632/hpc4rpv6j8.1

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Published: 13 October 2023| Version 1 | DOI: 10.17632/hpc4rpv6j8.1

Contributor:

Joslyn Kirby

Description

Supplementary appendix for an article "Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study" for The Journal of the American Academy of Dermatology

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Description

Files

Categories

Licence